The Health Technology Assessment (HTA) Council invites interested researchers to express interest and submit capsule proposals under the 2026 HTA Topics – Batch 2 Call [HTA General Track – Cycle 2 topics for Clinical, Economic and Ethical, Legal, Social, and Health Systems Impact (ELSHI) assessments; Pre-Cycle 1 topics for Economic and ELSHI Assessments]
The following are the health technology topics for assessments to be funded under this Call for Capsule Proposals:
HTA Topic for Full Assessment [Clinical, Economic (Cost Utility Analysis, Budget Impact Analysis, and Household Financial Impact Analysis (CUA, BIA + HFI Analysis)), and ELSHI]*
- Osimertinib as adjuvant treatment for early-stage Epidermal Growth Factor Receptor (EGFR)-positive non-small cell lung cancer (NSCLC) after tumor resection, as first-line treatment for locally advanced or metastatic EGFR-positive NSCLC (with subgroup analysis for brain metastasis), and as subsequent therapy for NSCLC patients who have progressed on first- and second-generation EGFR tyrosine kinase inhibitors (TKIs)
HTA Topic for Economic Assessment
For Model-Based Cost-Minimization Analysis (CMA) + BIA + HFI Analysis
- Dipeptidyl peptidase-4 (DPP-4) inhibitors (i.e., Sitagliptin and Vildagliptin) as add-on therapy to metformin compared with sulfonylureas or SGLT2 inhibitors, or metformin alone as primary analysis; and DPP-4 inhibitors (i.e., Sitagliptin and Vildagliptin) as add-on therapy to metformin compared with other DPP-4 inhibitors (i.e., Alogliptin and Saxagliptin) as secondary analysis for adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin monotherapy
HTA Topic for Ethical, Legal, Social, and Health Systems Impact (ELSHI) Assessment
- Dipeptidyl peptidase-4 (DPP-4) inhibitors (i.e., Sitagliptin and Vildagliptin) as add-on therapy to metformin compared with sulfonylureas or SGLT2 inhibitors, or metformin alone as primary analysis; and DPP-4 inhibitors (i.e., Sitagliptin and Vildagliptin) as add-on therapy to metformin compared with other DPP-4 inhibitors (i.e., Alogliptin and Saxagliptin) as secondary analysis for adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin monotherapy
*For the full assessment of osimertinib, the proponent must submit a capsule proposal for each assessment method (i.e., clinical, economic, and ELSHI).
For interested researchers, kindly take note of the following important dates:
- Deadline of expression of interest: 20 May 2026 (Wednesday)
- Deadline for submission of requirements: 10 working days from the submission of the expression of interest
Submissions shall be sent to htaresearch@dost.gov.ph
Kindly see the call guide and Terms of Reference for more info:
Call Guide:
Links to Terms of Reference:
| Topic Assessment | Link to TOR |
| Full Assessment | [2026 Batch 2 Full HTA] Osimertinib |
| Economic Assessment | [2026 Batch 2 model-based CMA] DPP-4 inhibitors |
| ELSHI Assessment | [2026 Batch 2 ELSHI] DPP4-inhibitors |